# Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct06350890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06350890](<https://clinicaltrials.gov/study/NCT06350890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06350890

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 408 participants.

## Technical summary

Registry record NCT06350890. Randomized; double masking; primary purpose treatment. Start 2023-11-05 (actual); primary completion 2024-12-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 408 participants (enrolled count; ClinicalTrials.gov record NCT06350890, source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)
- Started: 2023-11-05 (actual) (ClinicalTrials.gov record NCT06350890, source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)
- Primary completion: 2024-12-12 (actual) (ClinicalTrials.gov record NCT06350890, source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)
- Completion: 2025-08-04 (actual) (ClinicalTrials.gov record NCT06350890, source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06350890, source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06350890-2026-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
- Acronym: SYMPHONY-1
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): HTD1801
- Intervention (Drug): Placebo
- Lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd. (`cardio:org-shenzhen-hightide-biopharmaceutical-ltd`)

## Provenance

Content hash: d18cab552c8c6ee8cf8e8a3f5981b512f59a27cd4df38b32a71a27396dfd840c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
